Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Observations in vitro on the suitability of pyrazinamide for intermittent chemotherapy of tuberculosis.

× No keyword cloud information.

16 in total

1. Intermittent treatment regimens in pulmonary tuberculosis.

Authors: M Zierski
Journal: Lung Date: 1979 Impact factor: 2.584

2. Tuberculous infection.

Authors: D A Mitchison
Journal: Proc R Soc Med Date: 1971-05

Review 3. Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with meta-analyses.

Authors: Kwok Chiu Chang; Wing Wai Yew; Ying Zhang
Journal: Antimicrob Agents Chemother Date: 2011-07-18 Impact factor: 5.191

4. Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms.

Authors: S Sreevatsan; X Pan; Y Zhang; B N Kreiswirth; J M Musser
Journal: Antimicrob Agents Chemother Date: 1997-03 Impact factor: 5.191

5. Does pyrazinoic acid as an active moiety of pyrazinamide have specific activity against Mycobacterium tuberculosis?

Authors: L B Heifets; M A Flory; P J Lindholm-Levy
Journal: Antimicrob Agents Chemother Date: 1989-08 Impact factor: 5.191

6. Comparison of CO2 generation (BACTEC) and viable-count methods to determine the postantibiotic effect of antimycobacterial agents against Mycobacterium avium complex.

Authors: G G Zhanel; M H Saunders; J N Wolfe; D J Hoban; J A Karlowsky; A M Kabani
Journal: Antimicrob Agents Chemother Date: 1998-01 Impact factor: 5.191

Observations in vitro on the suitability of pyrazinamide for intermittent chemotherapy of tuberculosis.

1. Intermittent treatment regimens in pulmonary tuberculosis.

2. Tuberculous infection.

Review 3. Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with meta-analyses.

4. Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms.

5. Does pyrazinoic acid as an active moiety of pyrazinamide have specific activity against Mycobacterium tuberculosis?

6. Comparison of CO2 generation (BACTEC) and viable-count methods to determine the postantibiotic effect of antimycobacterial agents against Mycobacterium avium complex.

7. Pyrazinamide blood concentrations in children suffering from tuberculosis: a comparative study at two doses.

Review 8. Short-course therapy for tuberculosis.

9. In vitro postantibiotic effects of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis.

10. Postantibiotic effects of amikacin and ofloxacin on Mycobacterium fortuitum.